一个移动的目标：失活 BTK 突变作为滤泡性淋巴瘤的驱动基因。
A Moving Target: Inactivating BTK Mutations as Drivers of Follicular Lymphoma.
机构信息
Division of Hematology, Department of Medicine, University of Miami Miller School of Medicine, Miami, Florida.
Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, Miami, Florida.
出版信息
Clin Cancer Res. 2021 Apr 15;27(8):2123-2125. doi: 10.1158/1078-0432.CCR-21-0140. Epub 2021 Feb 12.
Abstract
Drugs that target Bruton tyrosine kinase (BTK) have been highly successful and changed the landscape of therapies in B-cell lymphomas. However, their lower rates of effectiveness in follicular lymphoma are unexplained. Recent work describes inactivating BTK mutations that show that at least some follicular lymphomas do not require BTK..
摘要
针对布鲁顿酪氨酸激酶（BTK）的药物已经取得了巨大的成功，并改变了 B 细胞淋巴瘤的治疗格局。然而，它们在滤泡性淋巴瘤中的疗效较低的原因尚不清楚。最近的研究描述了失活的 BTK 突变，表明至少一些滤泡性淋巴瘤不需要 BTK。
相似文献
1
A Moving Target: Inactivating BTK Mutations as Drivers of Follicular Lymphoma.
Clin Cancer Res. 2021 Apr 15;27(8):2123-2125. doi: 10.1158/1078-0432.CCR-21-0140. Epub 2021 Feb 12.
2
Follicular Lymphoma-associated BTK Mutations are Inactivating Resulting in Augmented AKT Activation.
Clin Cancer Res. 2021 Apr 15;27(8):2301-2313. doi: 10.1158/1078-0432.CCR-20-3741. Epub 2021 Jan 8.
3
Clinicopathological characteristics, outcomes and pattern of mutations in patients with follicular lymphoma who progressed on Bruton tyrosine kinase inhibitors.
Br J Haematol. 2018 Sep;182(5):718-723. doi: 10.1111/bjh.14857. Epub 2017 Aug 2.
4
The Evolving Role of Bruton's Tyrosine Kinase Inhibitors in B Cell Lymphomas.
Int J Mol Sci. 2024 Jul 9;25(14):7516. doi: 10.3390/ijms25147516.
5
Bruton tyrosine kinase inhibitors: a promising novel targeted treatment for B cell lymphomas.
Br J Haematol. 2013 Nov;163(4):436-43. doi: 10.1111/bjh.12573. Epub 2013 Sep 24.
6
Differential impact of BTK active site inhibitors on the conformational state of full-length BTK.
Elife. 2020 Nov 23;9:e60470. doi: 10.7554/eLife.60470.
7
Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma.
Cancer Discov. 2017 Sep;7(9):1018-1029. doi: 10.1158/2159-8290.CD-17-0613. Epub 2017 Jun 15.
8
Combination of Ibrutinib and ABT-199 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma.
Mol Cancer Ther. 2017 Jul;16(7):1246-1256. doi: 10.1158/1535-7163.MCT-16-0555. Epub 2017 Apr 20.
9
Ibrutinib inhibition of Bruton protein-tyrosine kinase (BTK) in the treatment of B cell neoplasms.
Pharmacol Res. 2016 Nov;113(Pt A):395-408. doi: 10.1016/j.phrs.2016.09.011. Epub 2016 Sep 15.
10
Bruton Tyrosine Kinase Inhibitors in B-Cell Malignancies: Their Use and Differential Features.
Target Oncol. 2022 Jan;17(1):69-84. doi: 10.1007/s11523-021-00857-8. Epub 2021 Dec 14.
引用本文的文献
1
BTK Promotes Atherosclerosis by Regulating Oxidative Stress, Mitochondrial Injury, and ER Stress of Macrophages.
Oxid Med Cell Longev. 2021 May 27;2021:9972413. doi: 10.1155/2021/9972413. eCollection 2021.
本文引用的文献
1
Follicular Lymphoma-associated BTK Mutations are Inactivating Resulting in Augmented AKT Activation.
Clin Cancer Res. 2021 Apr 15;27(8):2301-2313. doi: 10.1158/1078-0432.CCR-20-3741. Epub 2021 Jan 8.
2
Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma: Results From the Open-Label, Multicenter, Phase II DAWN Study.
J Clin Oncol. 2018 Aug 10;36(23):2405-2412. doi: 10.1200/JCO.2017.76.8853. Epub 2018 May 31.
3
Recurrent somatic mutations affecting B-cell receptor signaling pathway genes in follicular lymphoma.
Blood. 2017 Jan 26;129(4):473-483. doi: 10.1182/blood-2016-07-729954. Epub 2016 Nov 14.
4
Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib.
N Engl J Med. 2014 Jun 12;370(24):2286-94. doi: 10.1056/NEJMoa1400029. Epub 2014 May 28.
5
PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma.
N Engl J Med. 2014 Mar 13;370(11):1008-18. doi: 10.1056/NEJMoa1314583. Epub 2014 Jan 22.
Zotero 插件